10x Genomics Reports Second Quarter 2026 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
10x Genomics (TXG) Tops Q2 EPS by 10c, Beats on Revenue
August 6, 2026 4:22 PM EDT10x Genomics (NASDAQ: TXG) reported Q2 EPS of ($0.14), $0.10 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $151.04 million versus the consensus estimate of $146.64 million.
For earnings history and earnings-related data on 10x Genomics (TXG) click here.
... More